Abstract 111P
Background
In China, fruquintinib is approved for third-line treatment of patients with metastatic colorectal cancer(mCRC). There are no prospective randomized controlled studies comparing the efficacy of fruquintinib and fruquintinib in combination with immune checkpoint inhibitors (ICIs). In this study, we aimed to compare the efficacy and safety of fruquintinib monotherapy versus combination with ICIs in MSS mCRC.
Methods
We retrospectively analyzed mCRC patients who received fruquintinib in Sun Yat-sen University Cancer Center from January 2020 to January 2022. The primary endpoints were overall survival (OS), progression-free survival (PFS) and adverse events. The secondary endpoints were objective remission rate (ORR) and disease control rate (DCR).
Results
A total of 184 patients with mCRC were included in this study, and 61 patients received ICIs combined with fruquintinib. Most patients received second line and above treatment before the study treatment. The ORR of fruquintinib combined with ICIs group (Group A, n=61) and fruquintinib group (Group B, n=123) were 14.3% and 3.6%; the DCR were 55.1% and 39.8%, respectively. Group A had a significant longer median PFS than Group B (3.9 months vs 3.3 months, P=0.015). However, the median OS was no significant difference between the two groups (mOS: 9.3 months vs 7.9 months, P=0.414). In the third line and above, there was no statistically significant difference in OS and PFS between the two groups. Multivariate analysis showed that baseline liver metastasis and lactate dehydrogenase (LDH)of≥313.3 were associated with shorter PFS in those 184 patients. Adverse effects of two groups were generally similar (91.8% vs 93.2%, P=0.738), and the most common adverse effects of two groups were the hand–foot skin reaction, hoarseness and hypertension. The probability of treatment-related adverse events (TRAEs)of grade 3 or higher was broadly similar in both groups (14.1% vs 14.6%, P=0.916).
Conclusions
In the real world, there was no difference in OS and in the incidence of adverse events between patients with MSS mCRC patients treated with fruquintinib monotherapy versus in combination with ICIs.
Clinical trial identification
NCT04005066.
Editorial acknowledgement
Legal entity responsible for the study
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract